NCT03543150View on ClinicalTrials.gov

BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

UnknownOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Dysphonia
Interventions
DRUG

BOTOX

BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.

Trial Locations (1)

107-0052

RECRUITING

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY